Analysts Set Sage Therapeutics, Inc. (NASDAQ:SAGE) Target Price at $34.80

Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) have received a consensus recommendation of “Hold” from the twenty brokerages that are presently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, fifteen have given a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $34.80.

SAGE has been the subject of several research reports. Oppenheimer cut their price objective on Sage Therapeutics from $25.00 to $17.00 and set a “market perform” rating for the company in a research note on Thursday, April 18th. TD Cowen dropped their price target on Sage Therapeutics from $30.00 to $16.00 and set a “buy” rating for the company in a research report on Thursday, April 18th. Bank of America lowered Sage Therapeutics from a “neutral” rating to an “underperform” rating and lowered their price objective for the stock from $24.00 to $14.00 in a research note on Wednesday, April 17th. Wedbush reaffirmed a “neutral” rating and set a $24.00 target price on shares of Sage Therapeutics in a research note on Wednesday, April 17th. Finally, Mizuho dropped their price target on shares of Sage Therapeutics from $20.00 to $18.00 and set a “neutral” rating for the company in a research note on Friday, April 26th.

Sage Therapeutics Trading Down 1.9 %

Shares of Sage Therapeutics stock opened at $10.82 on Wednesday. Sage Therapeutics has a fifty-two week low of $9.76 and a fifty-two week high of $49.74. The firm has a 50-day simple moving average of $11.78 and a two-hundred day simple moving average of $18.07.

Sage Therapeutics (NASDAQ:SAGE) last issued its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.80) EPS for the quarter, missing the consensus estimate of ($1.63) by ($0.17). Sage Therapeutics had a negative net margin of 552.52% and a negative return on equity of 56.81%. The business had revenue of $7.90 million during the quarter, compared to analyst estimates of $5.26 million. During the same period in the previous year, the business posted ($2.46) earnings per share. The firm’s revenue for the quarter was up 139.4% on a year-over-year basis. On average, equities research analysts forecast that Sage Therapeutics will post -6.48 earnings per share for the current year.

Institutional Trading of Sage Therapeutics

Several institutional investors have recently modified their holdings of SAGE. Virtu Financial LLC purchased a new stake in Sage Therapeutics in the first quarter valued at $187,000. Baker BROS. Advisors LP acquired a new stake in shares of Sage Therapeutics in the 1st quarter valued at about $7,631,000. Bellevue Group AG grew its stake in Sage Therapeutics by 27.1% during the 1st quarter. Bellevue Group AG now owns 4,465,544 shares of the biopharmaceutical company’s stock worth $83,684,000 after buying an additional 952,193 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in Sage Therapeutics by 69.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 811,934 shares of the biopharmaceutical company’s stock worth $15,217,000 after buying an additional 333,805 shares during the period. Finally, Lazard Asset Management LLC purchased a new stake in Sage Therapeutics in the first quarter valued at approximately $127,000. Hedge funds and other institutional investors own 99.22% of the company’s stock.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.